Alicia K. Morgans
A5070812529- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Cancer, Lipids, and Metabolism
- Health Systems, Economic Evaluations, Quality of Life
- Radiopharmaceutical Chemistry and Applications
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Hormonal and reproductive studies
- Economic and Financial Impacts of Cancer
- Cancer survivorship and care
- Cancer Treatment and Pharmacology
- PARP inhibition in cancer therapy
- Pain Management and Opioid Use
- Advanced Breast Cancer Therapies
- COVID-19 and healthcare impacts
- Venous Thromboembolism Diagnosis and Management
- Multiple and Secondary Primary Cancers
- Bone health and treatments
- Cancer Genomics and Diagnostics
- Urinary and Genital Oncology Studies
- Statistical Methods in Clinical Trials
- Cardiac, Anesthesia and Surgical Outcomes
- COVID-19 Clinical Research Studies
Harvard University
2012-2025
Dana-Farber Cancer Institute
2018-2025
Dana-Farber Brigham Cancer Center
2022-2024
Brigham and Women's Hospital
2022-2024
Mayo Clinic Hospital
2024
University of California, San Diego
2024
Northwestern University
2017-2022
Hospital Universitario 12 De Octubre
2022
Instituto de Investigación Biomédica de Málaga
2022
Fred Hutch Cancer Center
2022
In advanced prostate cancer (APC), successful drug development as well advances in imaging and molecular characterisation have resulted multiple areas where there is lack of evidence or low level evidence. The Advanced Prostate Cancer Consensus Conference (APCCC) 2017 addressed some these topics. To present the report APCCC 2017. Ten important controversy APC management were identified: high-risk localised locally cancer; “oligometastatic” castration-naïve castration-resistant role APC;...
Innovations in treatments, imaging, and molecular characterisation advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 addressed some these topics supplement guidelines based on level 1 evidence.To present the results from APCCC 2019.Similar prior conferences, experts identified 10 important areas controversy regarding cancer:...
Substantial progress has been made in cancer diagnosis and treatment, resulting a steady improvement survival. The degree of by age, race, sex remains unclear.To quantify the survival over time United States.Longitudinal analyses follow-up data from 1990 to 2010, 1.02 million patients who had diagnosed as having colon or rectum, breast, prostate, lung, liver, pancreas, ovary 2009 were included 1 9 population-based registries National Cancer Institute Surveillance, Epidemiology, End Results...
The summary presented herein represents Part I of the three-part series dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment, staging, and risk-based management in patients diagnosed with clinically localized prostate cancer. Please refer Parts II III for discussion principles active surveillance, surgery follow-up (Part II), radiation future directions III).The systematic review utilized inform this guideline was conducted by an independent...
Germline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary assessment. Critical needs include optimized multigene strategies that incorporate evolving genetic data, consistency in GT indications alternate evaluation models address the rising demand for services. A multidisciplinary consensus conference included experts, stakeholders, national organization leaders was convened response to current practice challenges develop implementation...
The summary presented herein represents Part I of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with biochemical recurrence without metastatic disease after exhaustion local options as well those hormone-sensitive prostate cancer. Please refer II discussion management castration-resistant disease.The systematic review utilized inform this guideline was conducted by an independent...
The summary presented herein represents Part II of the three-part series dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing principles active surveillance and surgery as well follow-up for patients after primary treatment. Please refer Parts I III discussion risk assessment, staging, risk-based management (Part I), radiation future directions III).The systematic review utilized inform this guideline was conducted by an independent methodological consultant. A...
Innovations in imaging and molecular characterisation the evolution of new therapies have improved outcomes advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas management.To present consensus voting results for select questions from APCCC 2022.Before conference,...
Importance Adverse outcomes associated with treatments for localized prostate cancer remain unclear. Objective To compare rates of adverse functional between specific cancer. Design, Setting, and Participants An observational cohort study using data from 5 US Surveillance, Epidemiology, End Results Program registries. were treated 2011 2012. At baseline, 1877 had favorable-prognosis (defined as cT1-cT2bN0M0, prostate-specific antigen level <20 ng/mL, grade group 1-2) 568...
Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) surveyed experts key questions clinical management order supplement evidence-based guidelines. Here present voting results for from APCCC 2024.
Prior studies have shown that PI3Ks play a necessary but incompletely defined role in platelet activation. One potential effector for PI3K is the serine/threonine kinase, Akt, whose contribution to activation was explored here. Two isoforms of Akt were detected mouse platelets, with expression Akt2 being greater than Akt1. Deletion gene encoding impaired aggregation, fibrinogen binding, and granule secretion, especially response low concentrations agonists activate Gq-coupled receptors...
Prior studies have shown that PI3Ks play a necessary but incompletely defined role in platelet activation. One potential effector for PI3K is the serine/threonine kinase, Akt, whose contribution to activation was explored here. Two isoforms of Akt were detected mouse platelets, with expression Akt2 being greater than Akt1. Deletion gene encoding impaired aggregation, fibrinogen binding, and granule secretion, especially response low concentrations agonists activate Gq-coupled receptors...
To examine racial differences in the distribution of histological subtypes renal cell carcinoma (RCC) and associations with established RCC risk factors by subtype.Tumours from 1532 consecutive patients who underwent nephrectomy at Vanderbilt University Medical Center (1998-2012) were classified as clear-cell, papillary, chromophobe other subtypes. In pairwise comparisons, we used multivariate logistic regression to estimate odds ratios (ORs) 95% confidence intervals (CIs) for between race,...
Purpose The guideline aims to optimize health and quality of life for the post-treatment prostate cancer survivor by comprehensively addressing components follow-up care, including promotion, surveillance, screening new cancers, long-term late functional effects disease its treatment, psychosocial issues, coordination care between survivor's primary physician specialist. Methods American Cancer Society (ACS) Prostate Survivorship Care Guidelines were reviewed developmental rigor...
You have accessJournal of UrologyAUA Guideline1 Jan 2021Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II William T. Lowrance,*, Rodney H. Breau, Roger Chou, Brian F. Chapin, Tony Crispino, Robert Dreicer, David Jarrard, Adam S. Kibel, Todd M. Morgan, Alicia K. Morgans, Oh, Matthew J. Resnick, Anthony L. Zietman, and Michael Cookson Lowrance,*William Lowrance,* More articles by this author , BreauRodney Breau ChouRoger Chou ChapinBrian Chapin CrispinoTony Crispino DreicerRobert...
There are no universally monitored outcomes relevant to men with advanced prostate cancer, making it challenging compare health between populations. We sought develop a standard set of cancer follow during routine clinical care. The International Consortium for Health Outcomes Measurement assembled multidisciplinary working group the set. used modified Delphi method achieve consensus regarding outcomes, measures, and case mix factors included. 25 members international represented academic...
Abstract Ipilimumab, a novel immune checkpoint inhibitor, is associated with long-term survival in approximately 20% of patients advanced melanoma and also being evaluated the adjuvant setting. With this growing cohort survivors, health outcomes, chronic toxicities, functional outcomes among survivors treated ipilimumab need to be defined. Using retrospective medical record abstraction, we disease status, immune- non–immune-related events, pharmacologic management symptoms, status melanoma,...
354 Background: Patients (pts) with mUC who progress after platinum (PLT)-based chemotherapy and immune checkpoint inhibitor (CPI) therapy have poor outcomes limited treatment options. Sacituzumab govitecan (SG) is a novel antibody-drug conjugate. It consists of monoclonal antibody targeting Trop-2, an epithelial cell surface antigen overexpressed in UC, conjugated to the active metabolite irinotecan (SN38). Methods: We performed phase I/II basket study pts advanced solid tumors receiving...
The summary presented herein represents Part III of the three-part series dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing principles radiation and offering several future directions further relevant study in patients diagnosed with clinically localized prostate cancer. Please refer Parts I II for discussion risk assessment, staging, risk-based management (Part I), active surveillance surgery follow-up II).The systematic review utilized inform this guideline...
Analysis of DNA methylation is a valuable tool to understand disease progression and increasingly being used create diagnostic prognostic clinical biomarkers. While conversion cytosine 5-methylcytosine (5mC) commonly results in transcriptional repression, further 5-hydroxymethylcytosine (5hmC) associated with activation. Here we perform the first study integrating whole-genome 5hmC DNA, 5mC, transcriptome sequencing samples benign, localized, advanced prostate cancer. shown mark activation...